Package 60687-549-21

{"route": ["ORAL"], "spl_id": "23955366-9210-f95f-e063-6394a90a7e99", "openfda": {"nui": ["N0000175427", "N0000190114", "N0000185503", "N0000182137", "N0000187061"], "unii": ["A6IEZ5M406"], "rxcui": ["616749"], "spl_set_id": ["90c5a0c2-542c-467e-9c0c-ef320534c560"], "pharm_class_epc": ["Anti-anginal [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "manufacturer_name": ["American Health Packaging"]}, "finished": true, "packaging": [{"sample": false, "description": "30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-549-21)  / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (60687-549-11)", "package_ndc": "60687-549-21", "marketing_start_date": "20200819"}], "brand_name": "Ranolazine", "product_id": "60687-549_23955366-9210-f95f-e063-6394a90a7e99", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Anti-anginal [EPC]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "60687-549", "generic_name": "Ranolazine", "labeler_name": "American Health Packaging", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Ranolazine", "active_ingredients": [{"name": "RANOLAZINE", "strength": "500 mg/1"}], "application_number": "ANDA210054", "marketing_category": "ANDA", "marketing_start_date": "20200819", "listing_expiration_date": "20261231"}